**Clinical Research Study For Type 1 Diabetes Mellitus*
QR Code Link to This Post
We are seeking volunteers, age 18 and over, to participate in a research study comparing an investigational fast-acting insulin with NovoLog®.
You may qualify if you:
· Are currently taking insulin glargine, also known as Lantus®
· Use NovoLog® for bolus insulin at least 3 times per day
Participants not meeting this criterion may also qualify, provided that they complete the run-in period during which NovoLog and Lantus will be administered so that, at the time of randomization, the participants have been on NovoLog and insulin glargine (100 U/mL) for at least 12 weeks (including any potential pre-screening administration).
Alternating use of SAR341402 and NovoLog, self-administered by subcutaneous injection at mealtime, starting with NovoLog for the first 4 weeks, then SAR341402 for 4 weeks, followed by NovoLog for 4 weeks and then SAR341402 for the last 4 weeks on top of Lantus as basal insulin.
Continuous use of NovoLog, self-administrated by subcutaneous injection at mealtime, during the 16-week Treatment Period on top of Lantus as basal insulin.
Qualified Participants May Receive:
· Lantus® and investigational fast-acting insulin and/or NovoLog® (no placebo)
· Glucometer and testing supplies
· Payment for time and travel
APPLY HERE FOR STUDY: https://www.clinicalconnection.com/study-details/42563/posting?cl=42563